Gayle Jameson is a Nurse Practitioner who has cared for adults living with cancer for more than 45 years. She is an Advanced Oncology Certified Nurse (AOCN), and is especially interested in the care of patients with pancreatic cancer, early cancer drug development, and symptom management.
In her role as Associate Clinical Investigator at the Institute’s Oncology Research Division in Scottsdale, she has been Principal Investigator (PI) on multiple phase I, II, and investigator-initiated studies and Sub-Investigator on more than 100 phase I and II anti-tumor clinical trials.
She incorporates translational science in clinical trial designs by working with bench science colleagues at Translational Genomics Research Institute (TGen), Princeton University, Mayo Clinic, and Salk Institute for Biological Studies.
Gayle was the site Principal Investigator on an international study that led to the approval of nanoliposomal irinotecan (Onivyde™) plus 5FU and leucovorin for patients with metastatic pancreatic cancer. She published a study in JAMA Oncology 2020 that demonstrated significant improvement in the overall survival in patients with advanced pancreatic cancer.
Gayle has presented her work nationally and internationally. As a pioneer of the role of a N.P. as a Clinical Investigator in early Cancer Drug Development, she served as Founder and Co-Director of the “Inaugural Oncology Nurse Practitioner Clinical Investigator Intensive Course,” a collaborative project of the Institute and City of Hope, held at HonorHealth in 2018 and repeated in 2020. The course was again held in 2024 sponsored by HonorHealth and the Cottrell Foundation.
Gayle has also been honored as a recipient of the Oncology Nursing Society’s 2019 Lifetime Achievement Award, and the 2020 Luminary Award in GI Cancers by The Ruesch Center for the Cure of Gastrointestinal Cancers at Georgetown Lombardi Comprehensive Cancer Center.